

# LINCOLN PHARMACEUTICALS LIMITED

## Code of Conduct to Regulate, Monitor and Report Trading by Insiders.

1. This Code of Conduct will be known as "**LINCOLN PHARMACEUTICALS LIMITED: Code of Conduct to Regulate, Monitor and Report Trading by Insiders**" (hereinafter referred to as "**Code**").
2. This Code has been made pursuant to Regulation 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The Board of Directors have also formulated the Code in terms of Regulation 8 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (hereinafter referred to as the "**Regulations**").
3. In suppression of the previous insider trading code, **LINCOLN PHARMACEUTICALS LIMITED: Code of Conduct for Prohibition of Insider Trading** as framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, made effective from 15<sup>th</sup> May, 2015 is as under:

#### 4. Definitions:

4.1 "**Act**" means the Securities and Exchange Board of India Act, 1992 (15 of 1992).

4.2 "**Board**" means the Securities and Exchange Board of India.

4.3 "**Board of Directors**" means the Board of Directors of the Company.

4.4 "**Companies Act**" means The Companies Act, 2013.

4.5 "**Company**" or "**the Company**" means **LINCOLN PHARMACEUTICALS LIMITED**.

4.6 "**Compliance Officer**" means any senior officer appointed by the Board of Directors of the Company for the purpose of this Code and the Regulations, who shall be responsible for compliance of policies, procedures, maintenance of records, monitoring adherence to the rules for the preservation of unpublished price sensitive information, monitoring of trades and the implementation of the codes specified in these regulations.

4.7 "**Connected person**" means-

- (i) any person who is or has during the six months prior to the concerned act been associated with the Company, directly or indirectly, in any capacity including by reason of frequent communication with Company's officers or by being in any contractual, fiduciary or employment relationship or by being a director, officer or an employee of the Company or holds any position including a professional or business relationship between himself and the Company whether temporary or permanent, that allows such person, directly or indirectly, access to unpublished price sensitive information or is reasonably expected to allow such access.
- (ii) Without prejudice to the generality of the foregoing, the persons falling within the following categories shall be deemed to be connected persons unless the contrary is established –

## LINCOLN PHARMACEUTICALS LIMITED

- (a) an immediate relative of connected persons specified in clause (i); or
- (b) a holding company or associate company or subsidiary company; or
- (c) an intermediary as specified in section 12 of the Act or an employee or director thereof; or
- (d) an investment company, trustee company, asset management company or an employee or director thereof; or
- (e) an official of a stock exchange or of clearing house or corporation; or
- (f) a member of board of trustees of a mutual fund or a member of the board of directors of the asset management company of a mutual fund or is an employee thereof; or
- (g) a member of the board of directors or an employee, of a public financial institution as defined in section 2 (72) of the Companies Act, 2013; or
- (h) an official or an employee of a self-regulatory organization recognized or authorized by the Board; or
- (i) a banker of the company; or
- (j) a concern, firm, trust, Hindu undivided family, company or association of persons wherein a director of a company or his immediate relative or banker of the company, has more than ten per cent of the holding or interest.

**4.8 "Designated persons"** shall mean all employees in Finance, Accounts, Legal, Secretarial Department and such other employees who may be so designated, from time to time, by the Board of Directors for the purpose of this Code and who may be able to have access to any 'unpublished price sensitive information' as defined in this Code or the Regulations. Top Management of the Company shall include Board of Directors.

**4.9 "Generally Available Information"** means information that is accessible to the public on a non-discriminatory basis.

**4.10 "Immediate relative"** means a spouse of a person, and includes parent(s), sibling, and child of such person or of the spouse, any of whom is either dependent financially on such person, or consults such person in taking decisions relating to trading in securities.

**4.11 "insider"** means any person who is-

- (i) a connected person, or
- (ii) in possession of or having access to Unpublished Price Sensitive Information

Note: This definition intends to bring within its reach any person who is in receipt of or in possession of or have an access to unpublished price sensitive information.

**4.12 "key managerial personnel"**, in relation to the Company, means—

Persons as defined in Section 203 of the Companies Act, 2013 and such other persons / officer as may be designated as Key Managerial personnel by the Board of Director of the Company.

## LINCOLN PHARMACEUTICALS LIMITED

- 4.13 "promoter"** shall have the meaning assigned to it under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 or any modification thereof.
- 4.14 "securities"** shall have the meaning assigned to it under the Securities Contracts (Regulation) Act, 1956 (42 of 1956) or any modification thereof except units of a mutual fund.
- 4.15 "takeover regulations"** means the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and any amendments thereto.
- 4.16 "threshold limit"** means the value of the securities traded, whether in one transaction or a series of transactions over any calendar quarter, aggregating to a traded value of ten lakh rupees or such other value as may be specified by the regulatory authorities.
- 4.17 "trading"** means and includes subscribing, buying, selling, dealing, or agreeing to subscribe, buy, sell, deal in any securities, and "trade" shall be construed accordingly.
- 4.18 "trading day"** means a day on which the recognized stock exchanges are open for trading.
- 4.19 "trading window"** means a trading period for trading in the Company's Securities.
- 4.20 "unpublished price sensitive information"** means any information, relating to the Company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall, ordinarily including but not restricted to, information relating to the following: –
- (i) financial results;
  - (ii) dividends;
  - (iii) change in capital structure;
  - (iv) mergers, de-mergers, acquisitions, delisting, disposals and expansion of business and such other transactions;
  - (v) changes in key managerial personnel; and
  - (vi) material events in accordance with the listing agreement.

Words and expressions used and not defined in this code / regulations but defined in the Securities and Exchange Board of India Act, 1992 (15 of 1992), the Securities Contracts (Regulation) Act, 1956 (42 of 1956), the Depositories Act, 1996 (22 of 1996) or the Companies Act, 2013 (18 of 2013) and rules and regulations made there under shall have the meanings respectively assigned to them in those legislation.

## LINCOLN PHARMACEUTICALS LIMITED

### 5. Functions, duties and responsibilities of the Compliance Officer:

The Compliance Officer, subject to the supervision of the Board of Directors shall be responsible for:

- (1) Setting forth policies, procedures, monitoring adherence to the Code and Regulations for the preservation of unpublished price sensitive information, approval of trading plan, pre-clearance of trades and monitoring of trades and implementation of this Code.
- (2) Maintaining the record of the Promoters, Directors, Key Managerial Personnel, Designated Persons and other connected persons and incorporate changes from time to time.
- (3) Assisting all employees in addressing any clarifications in the Regulations or this Code.
- (4) Advising all Designated Persons not to trade in securities of the Company when the Trading Window is closed.
- (5) Advising all Directors, Promoters, Key managerial personnel and Designated Persons to furnish the details of transactions in the securities of the Company as stated in clauses 10-12 in the prescribed form and to maintain a record of all the intimations received for a period of at least five years.
- (6) Obtaining disclosures from Promoters, Directors, Key Managerial Personnel, Designated Persons and other connected persons and to give information, in respect of the disclosures received, to all the Stock Exchanges where the securities are listed, as applicable.
- (7) Maintaining records of all disclosures as stated in clauses 10-13 of this Code and to report the same to the Chairman of the Audit Committee, on a half yearly basis.

### 6. Communication or procurement of unpublished price sensitive information:

- (1) All information is to be handled on a **"need to know"** basis. It should be disclosed only to those within the Company who need the information to discharge their duty.
- (2) No insider shall communicate, provide, or allow access to any unpublished price sensitive information, relating to a Company or securities listed or proposed to be listed, to any person including other insiders except where such communication is in furtherance of legitimate purposes, performance of duties or discharge of legal obligations.
- (3) Files containing confidential information shall be kept secure. Computer files must have adequate security of login and password etc.
- (4) No person shall procure from or cause the communication by any insider of unpublished price sensitive information, relating to the Company or securities listed or proposed to be listed, except in furtherance of legitimate purposes, performance of duties or discharge of legal obligations.

## LINCOLN PHARMACEUTICALS LIMITED

- (5) Notwithstanding anything contained in this regulation, an unpublished price sensitive information may be communicated, provided, allowed access to or procured, in connection with a transaction that would:-
- (i) entail an obligation to make an open offer under the takeover regulations where the Board of Directors is of informed opinion that the proposed transaction is in the best interests of the Company;
  - (ii) not attract the obligation to make an open offer under the takeover regulations but where the Board of Directors is of informed opinion that the proposed transaction is in the best interests of the Company and the information that constitute unpublished price sensitive information is disseminated to be made generally available at least two trading days prior to the proposed transaction being effected in such form as the Board of Directors may determine.
  - (iii) For purposes of sub-clause (5) above, the Board of Directors shall require the parties to execute agreements to contract confidentiality and non-disclosure obligations on the part of such parties and such parties shall keep information so received confidential, except for the purpose of sub-clause (5) above, and shall not otherwise trade in securities of the Company when in possession of unpublished price sensitive information.

### **7. Restriction on trading when in possession of unpublished price sensitive information:**

- (1) No insider shall trade in securities of the Company which are listed or proposed to be listed on Stock Exchanges when in possession of unpublished price sensitive information.

Provided that the insider may prove his innocence by demonstrating the circumstances including the following: –

- i. the transaction is an off-market inter-se transfer between promoters who were in possession of the same unpublished price sensitive information without being in breach of regulation 3 and both parties had made a conscious and informed trade decision;
- ii. in the case of non-individual insiders: –
  - a. the individuals who were in possession of such unpublished price sensitive information were different from the individuals taking trading decisions and such decision-making individuals were not in possession of such unpublished price sensitive information when they took the decision to trade; and
  - b. appropriate and adequate arrangements were in place to ensure that these regulations are not violated and no unpublished price sensitive information was communicated by the individuals possessing the information to the individuals taking trading decisions and there is no evidence of such arrangements having been breached;
- iii. the trades were pursuant to a trading plan set up in accordance with regulation 8.

## LINCOLN PHARMACEUTICALS LIMITED

- (2) In the case of connected persons the onus of establishing that they were not in possession of unpublished price sensitive information shall be on such connected persons and in other cases the onus would be on the Board of Directors.
- (3) The Board may specify such standards and requirements, from time to time as it may deem necessary for the purpose of these regulations.
- (4) Insiders shall maintain the confidentiality of all unpublished price sensitive information. They shall, while in possession of any unpublished price sensitive information, neither trade in the securities of the Company on the basis of unpublished price sensitive information nor pass on such information to any person directly or indirectly by way of making a recommendation for trading in securities of the Company.

### **Prevention of misuse of unpublished price sensitive information:**

#### **8. Trading Plans:**

- (1) An insider shall be entitled to formulate a trading plan and present it to the Compliance Officer for approval and public disclosure pursuant to which trades may be carried out on his behalf in accordance with such plan.
- (2) Such trading plan shall:-
  - (i) not entail commencement of trading on behalf of the insider earlier than six months from the public disclosure of the plan;
  - (ii) not entail trading for the period between the twentieth trading day prior to the last day of any financial period for which results are required to be announced and the second trading day after the disclosure of such financial results;
  - (iii) entail trading for a period of not less than twelve months;
  - (iv) not entail overlap of any period for which another trading plan is already in existence;
  - (v) set out either the value of trades to be effected or the number of securities to be traded along with the nature of the trade and the intervals at, or dates on which such trades shall be effected; and
  - (vi) not entail trading in securities for market abuse.
- (3) The compliance officer shall review the trading plan to assess whether the plan would have any potential for violation of these regulations and shall be entitled to seek such express undertakings as may be necessary to enable such assessment and to approve and monitor the implementation of the plan.

## LINCOLN PHARMACEUTICALS LIMITED

- (4) The trading plan once approved shall be irrevocable and the insider shall mandatorily have to implement the plan, without being entitled to either deviate from it or to execute any trade in the securities outside the scope of the trading plan.

Provided that the implementation of the trading plan shall not be commenced if any unpublished price sensitive information in possession of the insider at the time of formulation of the plan has not become generally available at the time of the commencement of implementation and in such event the compliance officer shall confirm that the commencement ought to be deferred until such unpublished price sensitive information becomes generally available information.

- (5) Upon approval of the trading plan, the Compliance Officer shall notify the plan to the stock exchanges on which the securities are listed.

### 9. Trading Window :

- (1) Designated persons may execute trades subject to compliance with this Code and the Regulations. Towards this end, a notional trading window shall be used as an instrument of monitoring trading by the Designated Persons. The trading window shall be closed when the Compliance Officer determines that a Designated Person or class of Designated Persons can reasonably be expected to have possession of unpublished price sensitive information. Such closure shall be imposed in relation to such securities to which such unpublished price sensitive information relates. Designated Persons and their immediate relatives shall not trade in securities when the trading window is closed.
- (2) The trading window shall be applicable to any person having contractual or fiduciary relation with the Company, such as auditors, accountancy firms, law firms, analysts, consultants etc. and their immediate relatives, assisting or advising the Company.
- (3) The notice of closure of Trading Window intimated to the Stock Exchanges, if any, wherever the securities of the Company are listed, by the Compliance Officer, shall be deemed as intimation to the Designated Persons / Insiders for adherence and compliance with this Code.
- (4) The timing for re-opening of the trading window shall be determined by the Compliance Officer taking into account various factors including the unpublished price sensitive information in question becoming generally available and being capable of assimilation by the market, which in any event shall not be earlier than forty-eight hours after the information becomes generally available.
- (5) The "Trading Window" shall, inter-alia, remain closed from:
  - (i) the date of intimation, to the Stock Exchanges, of the date of Board Meeting/Committee Meeting until 48 hours after the following information is made generally available on following matters:
    - Declaration of financial results (quarterly, half-yearly and annually).
    - Declaration of dividends (interim and final).
    - Issue of securities by way of public/rights/bonus etc.

## LINCOLN PHARMACEUTICALS LIMITED

- Any major expansion plans or execution of new projects.
- Amalgamation, mergers, takeovers and buy-back.
- Disposal of whole or substantially whole of the undertaking.
- Any changes in policies, plans or operations of the company.
- Any other matters as may be specifically provided by SEBI or other Regulatory bodies from time to time.

(6) Trading Window may be closed by the Company during such time in addition to the above period, as it may deem fit by the Compliance Officer.

### 10. Pre-clearance of Trades:

- (1) When the trading window is open, trading by Designated Persons and their immediate relatives shall be subject to pre-clearance by the Compliance Officer, if the value of the proposed trades is above threshold limit. No Designated Person/their immediate relatives shall apply for pre-clearance of any proposed trade if they are in possession of unpublished price sensitive information even if the trading window is not closed.
- (2) Designated Persons / their immediate relatives intending to deal in the securities of the Company upto the threshold limit, as defined and provided hereinbefore, may do so without any pre-clearance from the Compliance Officer. In all other cases, they should pre-clear the transactions as per the pre-dealing procedure as provided hereinafter.
- (3) Designated Persons / their immediate relatives shall make an application in the prescribed Form I, to the Compliance Officer indicating the estimated number of securities that he/she intends to deal in, the details as to the depository(ies) with which he/she maintains a Demat/Trading account, the details as to the securities in such depository mode and such other details as may be required by the Compliance Officer in this matter.
- (4) He / She shall execute an undertaking in favour of the Company, incorporating, therein, inter alia, the following clauses:
  - that he/she does not have any access or has not received Unpublished Price Sensitive Information upto the time of signing the undertaking;
  - that in case he/she has access to or receives Unpublished Price Sensitive Information after the signing of the undertaking but before the execution of the transaction he/she shall inform the Compliance Officer of the change in his/her position and that he/she would completely refrain from dealing in the securities of the Company till the time such information becomes generally available;
  - that he/she has not contravened any provisions of this Code and the Regulations;
  - that he/she has made a full and true disclosure in the said matter.



## **LINCOLN PHARMACEUTICALS LIMITED**

- (5) The Compliance Officer shall confidentially maintain a list of such securities as a "restricted list" which shall be used as the basis for approving or rejecting applications for preclearance of trades.
- (6) Designated Persons / their immediate relatives shall execute their transactions in respect of securities of the Company within 7 (seven) trading days after the approval of pre-clearance is given by the Compliance Officer, failing which the transaction has to be pre-cleared again.
- (7) Reporting of trades executed or decisions not to trade and recording of such reasons shall be made/done in Form II. They shall not execute a contra trade during the six months following the prior transaction. In case of emergency the six months holding period may be waived by the Compliance Officer (application to be made in Form III) after recording in writing the reasons in this regard provided that such relaxation does not violate this Code/ Regulations.
- (8) In case of the Compliance Officer intending to deal in the securities of the Company beyond the threshold limit, the pre-clearance of the Chairman or in his absence the Managing Director of the Company, will have to be obtained. Similarly in case of emergency Compliance Officer may obtain the waiver from the Chairman or in his absence the Managing Director of the Company, provided that such relaxation does not violate this Code/ Regulations.
- (9) In case a contra trade is executed, inadvertently or otherwise, in violation of such a restriction, the profits from such trade shall be liable to be disgorged for remittance to the Board for credit to the Investor Protection and Education Fund administered by the Board under the Act.

### **Reporting Requirements:**

#### **11. Initial Disclosures:**

- (1) Every promoter, key managerial personnel and director of the Company shall disclose his holding of securities of the Company as on the date of this Code / regulations taking effect, to the Company within thirty days of this Code taking effect in Form A;
- (2) Every person on appointment as a Director or a Key Managerial Personnel of the Company or upon becoming a Promoter shall disclose his/her holding of securities of the Company as on the date of appointment or becoming a Promoter, to the Company within seven days of such appointment or becoming a promoter in Form B.

#### **12. Continual Disclosures:**

- (1) Every Promoters, Directors, Employees of the Company shall disclose to the Company in Form C the number of such securities acquired or disposed of within two trading days of such transaction, if the value of the securities traded, whether in one transaction or a series of transactions over any calendar quarter, exceeds the threshold limits as defined herein above;
- (2) The Company shall notify the particulars of such trading to the stock exchanges on which the securities are listed, as applicable, within two trading days of receipt of the disclosure or from becoming aware of such information.

## LINCOLN PHARMACEUTICALS LIMITED

- (3) The disclosure of the incremental transactions after any disclosure shall be made by persons as specified in (1) above, when the transactions effected after the prior disclosure crosses the threshold as defined above.

### **13. Disclosures by other connected persons:**

Any company whose securities are listed on a stock exchange may, at its discretion require any other connected person or class of connected persons to make disclosures of holdings and trading in securities of the company in such form and at such frequency as may be determined by the company in order to monitor compliance with these regulations.

#### **Note:**

1. Trading in securities shall also include trading in derivatives of securities and the traded value of the derivatives shall be taken into account for the purpose of making Initial/Continual disclosures as required in Clause 11 and 12 above.
2. Disclosures made under Clause 11 and 12 above shall include those relating to trading by such person's immediate relatives and by any other person for whom such person takes trading decisions.

### **14. Preservation of disclosures:**

The disclosures made under these regulations shall be maintained by the Compliance Officer, for a minimum period of five years.

### **15. Penalty for non-compliance of this Code:**

- (1) Any Promoter, Director, Employee or other connected person, or designated person who trades in securities or communicates any information for trading in securities in contravention of this Code, shall be penalized and appropriate action shall be taken against them by the Company after giving reasonable opportunity to them to show-cause. He/ she shall also be subject to disciplinary action, as deemed appropriate by the Board of Directors which may include wage freeze, suspension, in-eligibility for future participation in ESOPs etc.
- (2) In addition to the action which may be taken by the Company, the persons violating the Regulations or this Code shall also be subject to action under SEBI Act. In case of any violation, the Board of Directors shall inform the Board accordingly.

### **16. Chinese Wall:**

To prevent the misuse of confidential information the Company shall adopt a "Chinese Wall" policy which separates those areas of the Company which routinely have access to confidential information, considered "inside areas" from those areas which deal with sales/marketing or other departments providing support services, considered "public areas".

## **LINCOLN PHARMACEUTICALS LIMITED**

The employees in the inside area shall not communicate any Price Sensitive Information to anyone in public area.

In exceptional circumstances employees from the public areas may be brought "over the wall" and given confidential information strictly on the basis of "need to know" criteria, under intimation to the Compliance Officer.

### **17. General:**

The decision of the Board of Directors with regard to any or all matters relating to this Code shall be final and binding on all concerned. The Board of Directors shall have the power to modify, amend or replace this Code in part or full, as may be thought fit from time to time in their absolute discretion.

**LINCOLN PHARMACEUTICALS LIMITED**  
**Principles of Fair Disclosure for purposes of Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information**

[Under Regulation 8(1) of SEBI (Prohibition of Insider Trading) Regulations, 2015]

1. Prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being in order to make such information generally available.
2. Uniform and universal dissemination of unpublished price sensitive unpublished price sensitive information to avoid selective disclosure.
3. Designation of a senior officer as a chief investor relations officer to deal with dissemination of information and disclosure of unpublished price sensitive information.
4. Prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise to make such information generally available.
5. Appropriate and fair response to queries on news reports and requests for verification of market rumours by regulatory authorities.
6. Ensuring that information shared with analysts and research personnel is not unpublished price sensitive information.
7. Developing best practices to make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the official website to ensure official confirmation and documentation of disclosures made.
8. Handling of all unpublished price sensitive information on a need-to-know basis.

**18. Forms:**

(1) **Disclosure Forms:**

- Form A : Form for Initial Disclosures under clause 11(1)
- Form B : Form for Initial Disclosures under clause 11(2)
- Form C : Form for Continual Disclosures under clause 12 (1)

(2) **Internal Forms:**

- Form I : Application for Pre-Clearance and undertaking
- Form II : Reporting of trades executed/decisions not to trade and recording of such reasons
- Form III : Application for waiver of minimum holding period

**LINCOLN PHARMACEUTICALS LIMITED**  
**Form I**

**LINCOLN PHARMACEUTICALS LIMITED**

**FORMAT OF APPLICATION FOR OBTAINING PRE-CLEARANCE APPROVAL**

**[Clause 10(3) of LINCOLN PHARMACEUTICALS LIMITED: Code of Conduct to Regulate, Monitor and Report Trading by Insiders]**

Date\_\_\_\_\_

The Compliance Officer,

**LINCOLN PHARMACEUTICALS LIMITED**

LINCOLN HOUSE , Behind Satyam Complex,

Science City Road, Sola,

Ahmedabad – 380060

Dear Sir,

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Lincoln Pharmaceuticals Limited: Code of Conduct to Regulate, Monitor and Report Trading by Insiders, I seek approval to purchase/sale/subscribe for not more than\_\_\_\_\_ securities of the Company (having approximately Market value of Rs.\_\_\_\_ as on the date of application) as per the details given below:

1.	Name of the Designated Person	
2.	Designation	
3.	Number of securities held as on date	
4.	Folio No./DP ID/Client ID	
5.	Estimated number of securities proposed to purchase/sale/subscribe	
6.	Estimated price at which the transaction is proposed be executed	
7.	Whether the transaction would be through Stock Exchange or off-market deal	
8.	In case of Off-market deal, Folio no./DP ID/Client ID where the securities will be credited	

Yours truly,

\_\_\_\_\_  
(Signature of the Designated Person)

(Name of the Designated Person)

**LINCOLN PHARMACEUTICALS LIMITED**

**LINCOLN PHARMACEUTICALS LIMITED  
FORMAT OF UNDERTAKING TO BE ACCOMPANIED WITH THE APPLICATION FOR  
OBTAINING PRE-CLEARANCE APPROVAL**

**UNDERTAKING**

Date \_\_\_\_\_

The Compliance Officer,  
**LINCOLN PHARMACEUTICALS LIMITED**  
LINCOLN HOUSE, Behind Satyam Complex,  
Science City Road, Sola,  
Ahmedabad – 380060

I, .....(Name of the Designated Person),..... (designation) of the Company residing at .....(address of the Designated Person) hereby declare that I am not in possession of any Unpublished Price Sensitive Information (as defined in the Lincoln Pharmaceuticals Limited: Code of Conduct to Regulate, Monitor and Report Trading by Insiders) upto the date of signing of this Undertaking.

I further declare that in case I have access to any Unpublished Price Sensitive Information after the signing of Undertaking and before the execution of Trade for which Pre-clearance is requested in Form I (enclosed), I shall:

1. Promptly inform the Compliance Officer.
2. Refrain from trading in securities of the Company.
3. Apply afresh for obtaining pre-clearance approval from the Compliance Officer of the Companying Form I only after 2 days of such Unpublished Price Sensitive Information becoming public.

Upon obtaining preclearance for trading in securities of the Company, I undertake to execute the transaction within seven (7) trading days failing which I shall seek pre-clearance again.

I undertake to submit **Form II** within 4 working days of execution of the transaction/ a NIL report in case the transaction is not executed.

I declare that I have made true and complete disclosure in the matter.

Yours truly,

\_\_\_\_\_  
(Signature of the Designated Person)  
(Name of the Designated Person)

**LINCOLN PHARMACEUTICALS LIMITED  
Form II**

**LINCOLN PHARMACEUTICALS LIMITED**

**FORMAT FOR DISCLOSURE OF TRANSACTIONS EXECUTED/NOT EXECUTED AFTER OBTAINING  
PRE-CLEARANCE**

**[Clause 10(7) of LINCOLN PHARMACEUTICALS LIMITED: Code of Conduct to Regulate, Monitor and  
Report Trading by Insiders]**

Date\_\_\_\_\_

The Compliance Officer,

**LINCOLN PHARMACEUTICALS LIMITED**

LINCOLN HOUSE, Behind Satyam Complex,

Science City Road, Sola,

Ahmedabad – 380060

With reference to trading approval granted by the Compliance Officer / Company to me on \_\_\_\_, I hereby inform that I have bought/sold/subscribed for \_\_\_\_ equity shares of the Company for Rs.\_\_\_\_ on \_\_\_\_.

In connection with the aforesaid transaction, please find enclosed copy of the following for your records:

Broker's contract note/Proof of payment to/from brokers/ Extract of bank passbook/statements (in case of demat transaction)/ Copy of Delivery instruction slips (applicable in case of sale transactions)

I hereby undertake to preserve the original copy of the above mentioned document for a period of 5 years) and produce to the Compliance Officer/Securities Exchange Board of India, if required in future.

Yours truly,

\_\_\_\_\_  
(Signature of the Designated Person)

(Name of the Designated Person)

**Note:** After pre-clearance, if the Designated Person opts not to trade in securities should provide the reasons for taking such decision.



**LINCOLN PHARMACEUTICALS LIMITED**

**Form III**

**LINCOLN PHARMACEUTICALS LIMITED**

**APPLICATION FOR WAIVER OF MINIMUM HOLDING PERIOD**

**[Clause 10(7) of LINCOLN PHARMACEUTICALS LIMITED: Code of Conduct to Regulate, Monitor and Report Trading by Insiders]**

Date\_\_\_\_\_

The Compliance Officer,

**LINCOLN PHARMACEUTICALS LIMITED**

LINCOLN HOUSE, Behind Satyam Complex,  
Science City Road, Sola,  
Ahmedabad – 380060

Dear Sir,

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Lincoln Pharmaceuticals Limited: Code of Conduct to Regulate, Monitor and Report Trading by Insiders, I .....  
(Name and designation of the Designated Person) had ..... (provide the details of purchase/sale/subscribe for shares as the case may be) ..... (number of securities) of the Company on \_\_\_ after obtaining pre-clearance on \_\_\_. The details of transaction executed were submitted on \_\_\_(date) in Form II. I seek your approval to waive off the time restrictions and permit to execute a contra-trade for .....(number of securities) of the Company due to .....  
(valid reason(s) for executing contra trade).

I declare that I am not in possession of any Unpublished Price Sensitive Information (as defined in the Lincoln Pharmaceuticals Limited: Code of Conduct to Regulate, Monitor and Report Trading by Insiders) upto the date of this application.

I further declare that in case I have access to any Unpublished Price Sensitive Information after the signing of this application and before executing a contra Trade (if permitted), I shall:

1. Promptly inform the Compliance Officer
2. Refrain from trading in securities of the Company.

Yours truly,

\_\_\_\_\_  
(Signature of the Designated Person)

(Name of the Designated Person)

Enclosed:

1. Copy of pre-clearance approval
2. Copy of Form I & II